best peptides FAQ

Cerebrolysin may support cognitive recovery after thiamine repletion, but it does not replace thiamine. Wernicke-Korsakoff syndrome results from thiamine deficiency causing neuronal death in the thalamus and mammillary bodies. Damage that is partially permanent. Cerebrolysin provides neurotrophic support for surviving neurons, potentially improving memory consolidation and executive function, but cannot regenerate dead tissue. Administer thiamine (500mg IV daily for 3–5 days) first, then consider Cerebrolysin as adjunct therapy for residual cognitive deficits 4–6 weeks post-acute treatment.

No documented receptor competition exists between BPC-157, TB-500, and GHK-Cu because they act on distinct molecular pathways. VEGF/FGF signaling, actin dynamics, and MMP/TIMP balance respectively. Research models using concurrent administration show additive rather than antagonistic effects. The primary concern is injection site irritation when multiple peptides are administered subcutaneously in the same region on the same day. Rotate injection sites or separate administration by 6–8 hours.

Reduce the dose to 0.75–1.0mg for the next administration and ensure you're not taking it on an empty stomach. Nausea from PT-141 is dose-dependent and peaks 30–60 minutes post-injection due to melanocortin receptor activation in the area postrema (the brain's chemoreceptor trigger zone). Most users adapt after 2–3 doses, but if nausea persists beyond 4 hours or includes vomiting, discontinue use and consult the prescribing provider. Severe nausea in 5–8% of trial participants required antiemetic intervention.

Nicotine replacement addresses receptor binding but not the dopamine depletion, GABA suppression, or immune rebound that occur during withdrawal. Peptide protocols target those secondary systems. Selank for GABAergic tone, P21 for cognitive recovery, Thymalin for immune restoration. Research suggests combining NRT with peptide support produces higher sustained abstinence than either approach alone, likely because the peptides stabilize the neurochemical systems NRT doesn't touch.

Do not reconstitute it. Lyophilised peptides should appear as a uniform white or off-white powder. Clumping suggests moisture exposure during shipping, and discolouration (yellow, brown, pink) indicates oxidation or microbial contamination. Moisture-exposed peptides lose 30–70% potency even if they reconstitute visually clear, and oxidised peptides can form aggregates that trigger immune responses when injected. Contact the supplier immediately for replacement. Reputable sources like Real Peptides replace compromised shipments without question because peptide stability during transit is a known risk.

Pain reduction is not structural recovery. Peptides modulate pain signaling faster than they rebuild tendon tensile strength. Resuming full-intensity gripping or lifting at week 3–4 because you feel fine risks re-tearing partially healed tissue. Follow the staged return protocol: 50% intensity at week 6, 75% at week 8, full intensity at week 10–12, with pain-free eccentric testing before each progression.

Use growth hormone secretagogues. CJC-1295 combined with ipamorelin or tesamorelin alone. These peptides mobilise visceral fat through the JAK2/STAT5 lipolytic pathway without affecting gastric emptying or central appetite signalling. Standard dosing is 200–300mcg of each peptide injected subcutaneously once or twice daily under fasted conditions. The drawback: visceral fat reduction with GH secretagogues is slower and less pronounced than GLP-1 agonists. Expect 6–8% loss over 12–16 weeks versus 12–15% with tirzepatide at the same duration.

Yes, peptides and topical estrogen target different pathways and can be used concurrently. Use estrogen (typically estriol 0.5 mg) in the morning and peptide gel at night to avoid carrier interference. Estrogen bases are often oil-based while peptide bases are water-based, and mixing them reduces absorption efficiency for both compounds. Monitor for any increase in irritation during the first two weeks; if it occurs, reduce peptide concentration by 50% and re-escalate gradually.

Review reconstitution and storage protocols first. Peptides stored above 8°C or reconstituted incorrectly lose bioactivity without visible degradation. If storage was correct, consider switching to combined BPC-157 and TB-500 therapy. Some tendinopathies respond better to dual-mechanism protocols. If no improvement occurs after 6 weeks of combined therapy, imaging (MRI or ultrasound) may reveal calcific tendinosis or partial tendon tears requiring surgical intervention.

Check whether you've reached therapeutic dose and maintained it for at least 12 weeks. The NEJM NASH trial used 2.4mg weekly for 72 weeks. Hepatic outcomes at lower doses or shorter durations weren't significant. ALT and AST reductions typically lag behind weight loss by 8–12 weeks because hepatic steatosis reversal is a slower process than adipose tissue mobilisation. If enzymes remain elevated after 16 weeks at target dose, imaging (MRI-PDFF or FibroScan) provides more accurate steatosis and fibrosis assessment than bloodwork alone.

CJC-1295 without DAC (Mod GRF 1-29) has a 30-minute half-life. If you're dosing once daily, you're only getting brief GH pulses that may not sustain hepatic IGF-1 production. Increase dosing frequency to 2–3 times daily (morning, post-workout, before bed) to maintain more consistent GH elevation. Alternatively, switch to CJC-1295 with DAC for sustained weekly release, or add a GHRP like ipamorelin to amplify each pulse. Monotherapy with short-acting GHRHs rarely produces the IGF-1 increases seen in combination protocols.

Thyroid and HPA dysfunction often coexist—chronic stress suppresses thyroid hormone conversion (T4 to active T3) and increases reverse T3, creating functional hypothyroidism even when TSH looks normal. Thymalin and MK-677 don't directly interact with thyroid hormone replacement, but they can improve conversion efficiency by reducing inflammatory cytokines that block deiodinase enzymes. If you're on levothyroxine or liothyronine, monitor your symptoms—you may need dosage adjustments as HPA function improves and thyroid hormone utilization becomes more efficient. Coordinate with your prescribing physician before starting any peptide protocol alongside thyroid medication.

Not all OCD is driven by BDNF deficits. Some cases involve glutamate excess, immune dysregulation, or dopamine imbalances that neurotrophic peptides don't address. If Cerebrolysin or Semax produce no subjective or objective improvement after 4–6 weeks at therapeutic dosing, shift focus to peptides with alternative mechanisms: Selank for GABA modulation, P21 for glutamate dampening, or Thymalin in immune-mediated OCD cases. Peptide non-response often signals the need for pathway-specific targeting rather than compound failure. OCD is heterogeneous, and matching mechanism to underlying pathology is critical.

PT-141 is the peptide designed specifically for this scenario. Hypoactive sexual desire disorder in premenopausal women with normal estrogen and testosterone is precisely the indication for which bremelanotide received FDA approval. The RECONNECT trials excluded women with hormone deficiencies to isolate the central dopaminergic effect. If standard hormone panels (estradiol, total and free testosterone, DHEA-S) return within normal ranges but libido remains impaired, PT-141's melanocortin-4 receptor mechanism bypasses the hormonal pathway entirely.

Switching compounds immediately is premature—immune recovery and tissue repair operate on timescales measured in weeks to months, not days. Thymalin's T-cell modulation requires 10-day cycles to influence lymphocyte populations, and TB-500's tissue-repair signaling needs 4–6 weeks to manifest in functional recovery metrics. If no improvement occurs after completing a full protocol duration (10 days for Thymalin, 4–6 weeks for TB-500/BPC-157), reassess the injury profile—neurological presentations require different peptides than cardiac or immune-specific injuries. Storage and reconstitution errors account for 30–40% of reported "non-response" cases—verify that peptides were stored at 2–8°C continuously and reconstituted with correct solvents.

Acute + chronic phase pairing works: Cerebrolysin (acute neuroprotection) followed by Dihexa (chronic neuroplasticity) addresses sequential injury phases without overlapping mechanisms. Avoid combining peptides with redundant pathways. Stacking two BDNF mimetics achieves no additive benefit and increases cost without improving outcomes. Inflammation modulators like Thymalin pair well with neuroplasticity compounds because they target orthogonal mechanisms.

Start with KPV for immediate anti-inflammatory support. 500–1000mcg subcutaneously daily reduces symptom severity (fatigue, joint pain, cognitive fog) within 7–14 days without suppressing the immune response required to control viral replication. Thymalin should be added after the acute phase (2–4 weeks into KPV) to address the underlying immune deficiency that allowed reactivation. Starting both simultaneously risks overwhelming an already exhausted immune system with conflicting signals.

Use Hexarelin at 100–200mcg subcutaneously before anticipated stressors. Research models show 14–22% blunting of ACTH-driven cortisol surges without affecting basal cortisol levels. This peptide works through ghrelin receptor pathways that modulate the acute stress response, not chronic HPA axis output. Cycle 5 days on / 2 days off to prevent receptor downregulation, which occurs with continuous daily dosing beyond 4–6 weeks. Pair with magnesium glycinate (400mg daily) to support GABA receptor function and amplify the stress-blunting effect.

Epithalamin, DSIP, and Selank have decades of research in Eastern European clinical settings with no documented organ toxicity or dependency at therapeutic doses. The primary safety consideration is purity and sourcing. Compounded peptides from unverified suppliers may contain bacterial endotoxins or incorrect amino acid sequences that cause immune responses. Work only with suppliers providing third-party purity verification (HPLC and mass spectrometry) and consider peptides as periodic interventions (10-day cycles every 3–6 months) rather than daily indefinite use.

NSAID-induced ulcers occur because COX-1 inhibition reduces prostaglandin E2, which normally protects the gastric mucosa by stimulating mucus and bicarbonate secretion. TB-500 may help by accelerating epithelial migration even while prostaglandin synthesis remains suppressed. The peptide doesn't restore prostaglandin levels. It bypasses that pathway entirely by enhancing the mechanical process of epithelial cells moving across the ulcer bed. Dosing protocols in wound healing studies typically use 2–10 mg subcutaneously twice weekly.